ImpediMed Ltd
ASX:IPD
ImpediMed Ltd
Total Receivables
ImpediMed Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImpediMed Ltd
ASX:IPD
|
Total Receivables
AU$3.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
19%
|
|
|
Somnomed Ltd
ASX:SOM
|
Total Receivables
AU$18.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
10%
|
|
|
Cochlear Ltd
ASX:COH
|
Total Receivables
AU$564.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Total Receivables
AU$3.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
60%
|
CAGR 10-Years
21%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Total Receivables
AU$24.4m
|
CAGR 3-Years
47%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Total Receivables
AU$5.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
What is ImpediMed Ltd's Total Receivables?
Total Receivables
3.7m
AUD
Based on the financial report for Jun 30, 2025, ImpediMed Ltd's Total Receivables amounts to 3.7m AUD.
What is ImpediMed Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
19%
Over the last year, the Total Receivables growth was 14%. The average annual Total Receivables growth rates for ImpediMed Ltd have been -6% over the past three years , -4% over the past five years , and 19% over the past ten years .
